shisheng ling/E+ via Getty Images
- Novo Nordisk (NVO) has reduced the price of its GLP-1 medication Wegovy (semaglutide) in China, where it is approved for weight reduction.
- List prices for the two highest dosage strengths were cut by nearly 50% in several provinces, according to local media,
Follow us on Google for the latest stock news